BHRT & TRT for Men: Evidence, Protocols & Optimization

Testosterone replacement therapy (TRT) and bioidentical hormone replacement therapy (BHRT) for men have moved from the fringes of anti-ageing medicine into mainstream clinical practice. Yet significant confusion remains around who is a candidate, which protocols are safest, how to monitor effectively, and how integrative strategies can optimise outcomes. This guide covers the evidence base, delivery methods, protocols, side effect management, and the root cause approach to male hormonal health.

Understanding Male Hormonal Decline

The Andropause Continuum

Unlike the relatively abrupt hormonal shift of female menopause, male testosterone decline is gradual — approximately 1–2% per year after age 30. By age 70, most men have testosterone levels 30–50% lower than their peak. This gradual decline, sometimes called andropause or late-onset hypogonadism (LOH), is associated with a progressive constellation of symptoms that are frequently misattributed to normal ageing.

Diagnosing Hypogonadism

Clinical hypogonadism is defined as low testosterone combined with symptoms. Biochemical thresholds vary by laboratory, but most guidelines use:

• Total testosterone <300 ng/dL — consistent with hypogonadism (Endocrine Society guideline)
• Free testosterone <65 pg/mL — functionally low, especially when SHBG is elevated
• Two morning fasting measurements on separate days required for diagnosis
• Symptoms must be present — biochemical low T without symptoms does not require treatment

Symptoms of Low Testosterone in Men

• Fatigue and reduced energy — often the first and most prominent complaint
• Reduced libido and sexual dysfunction (erectile dysfunction, reduced morning erections)
• Loss of muscle mass and strength (sarcopenia)
• Increased body fat, especially visceral/abdominal
• Brain fog, poor concentration, and memory decline
• Depression, irritability, and reduced motivation
• Poor sleep quality and insomnia
• Reduced bone density (osteopenia/osteoporosis)
• Anaemia (testosterone stimulates erythropoiesis)
• Reduced body and facial hair; testicular atrophy

Root Causes of Low Testosterone

Primary Hypogonadism (Testicular Failure)

• Klinefelter syndrome (XXY)
• Orchitis (viral, autoimmune)
• Testicular trauma or torsion
• Chemotherapy or radiation damage
• Elevated FSH/LH with low T = primary hypogonadism

Secondary Hypogonadism (Hypothalamic-Pituitary Dysfunction)

• Obesity and insulin resistance — the most common cause of secondary hypogonadism; adipose tissue aromatises testosterone to oestrogen and suppresses LH pulsatility
• Chronic stress and HPA axis dysregulation — elevated cortisol suppresses GnRH and LH
• Sleep deprivation — 70% of daily testosterone is released during sleep; poor sleep acutely suppresses T
• Opioid use — opioid-induced androgen deficiency (OPIAD) is common and underrecognised
• Anabolic steroid use/abuse — suppresses the HPG axis; recovery may be incomplete
• Hyperprolactinaemia — elevated prolactin suppresses GnRH; rule out pituitary adenoma
• Haemochromatosis — iron deposition in the pituitary impairs gonadotropin secretion
• Nutritional deficiencies — zinc, vitamin D, and magnesium are essential for testosterone synthesis

Oestrogen Excess in Men

Elevated oestradiol in men — driven by aromatase activity in adipose tissue, liver dysfunction, or xenoestrogen exposure — suppresses LH and testosterone production, causes gynaecomastia, and worsens symptoms of low T even when testosterone levels are borderline. See our Oestrogen Excess in Men article for full detail.

TRT Delivery Methods

Injectable Testosterone

• Testosterone cypionate or enanthate — most common; typically 100–200 mg IM or SubQ every 7–14 days
• Testosterone undecanoate (Aveed/Nebido) — long-acting; injected every 10–14 weeks; more stable levels but less flexibility for dose adjustment
• SubQ vs IM — subcutaneous injection (insulin needle, abdomen or thigh) produces slower absorption, more stable levels, and is preferred by many patients for self-administration
• Pros: cost-effective, flexible dosing, reliable absorption
• Cons: peaks and troughs with less frequent dosing; requires self-injection or clinic visits

Topical Gels & Creams

• Testosterone gel (AndroGel, Testim, Tostran) applied daily to shoulders, upper arms, or abdomen
• Compounded testosterone cream — often applied to scrotum for enhanced absorption (scrotal skin has 5× higher permeability)
• Pros: stable daily levels; no injections; easy to adjust dose
• Cons: transfer risk to partners/children; variable absorption; serum monitoring less reliable than injectable

Transdermal Patches

• Applied nightly; mimic natural diurnal testosterone rhythm
• Pros: physiological delivery pattern
• Cons: skin irritation common; less popular than gels

Pellet Therapy

• Bioidentical testosterone pellets implanted subcutaneously (hip/buttock) every 3–6 months
• Pros: consistent levels; no daily administration; high patient satisfaction
• Cons: irreversible once implanted for the cycle; infection risk; dose adjustment requires new insertion; not FDA-approved (compounded)

Oral & Buccal Options

• Testosterone undecanoate oral (Jatenzo, Tlando) — FDA-approved oral T; taken with food; avoids first-pass metabolism via lymphatic absorption
• Buccal testosterone (Striant) — applied to gum twice daily; less commonly used

Protocols & Dosing Principles

Starting TRT

• Establish baseline labs before initiating (see Monitoring section)
• Start low and titrate: testosterone cypionate 100 mg/week SubQ is a common starting pointAllow 6–8 weeks before assessing response and adjusting dose
• Target total testosterone mid-normal range (500–800 ng/dL) and free testosterone upper-normal range
• Symptom resolution is the primary endpoint — not a specific number

Managing Oestrogen on TRT

Exogenous testosterone aromatises to oestradiol. Some oestrogen is essential for men (bone health, libido, cardiovascular protection, cognitive function) — the goal is balance, not elimination.

• Target oestradiol: 20–40 pg/mL (sensitive assay) on TRT
• Aromatase inhibitors (AI) — anastrozole or exemestane used when oestradiol is elevated and symptomatic (gynaecomastia, water retention, mood changes). Use cautiously — over-suppression of oestrogen causes joint pain, low libido, cardiovascular risk, and bone loss
• Natural aromatase support — zinc, DIM, calcium D-glucarate, weight loss (reduces adipose aromatase activity)

Fertility Preservation on TRT

Exogenous testosterone suppresses the HPG axis, reducing LH/FSH and causing testicular atrophy and azoospermia. Men wishing to preserve fertility should consider:

• hCG (human chorionic gonadotropin) — mimics LH; maintains intratesticular testosterone production and testicular volume. Typically 500–1,000 IU SubQ 2–3×/week alongside TRT
• Clomiphene citrate (Clomid) — SERM that stimulates endogenous LH/FSH; raises testosterone without suppressing the axis; preferred for men wanting to maintain fertility or avoid exogenous T
• Enclomiphene — the active isomer of clomiphene; cleaner profile with less visual side effects

Testicular Atrophy Prevention

• hCG co-administration is the most effective strategy
• Some protocols cycle TRT with hCG-only periods

Monitoring on TRT

Baseline Labs (Before Starting)

• Total testosterone (AM, fasting ×2 on separate days)
• Free testosterone, SHBG
• LH, FSH (to distinguish primary vs secondary hypogonadism)
• Oestradiol (sensitive assay)
• PSA (prostate-specific antigen) — baseline before TRT in men over 40
• Full blood count (haematocrit/haemoglobin) — TRT increases red blood cell production
• Comprehensive metabolic panel, lipid panel
• Prolactin, thyroid panel (TSH, free T3)
• DHEA-S, cortisol (AM)
• Vitamin D, zinc, magnesium

Follow-Up Monitoring

• Labs at 6–8 weeks after initiation or dose change: total T, free T, oestradiol, haematocrit
• PSA at 3–6 months, then annually
• Haematocrit: if >54%, hold TRT and investigate (therapeutic phlebotomy may be needed)
• Annual: full panel including lipids, metabolic panel, PSA, haematocrit
• DEXA scan at baseline and every 2 years (bone density)

Integrative Optimization Strategies

Lifestyle Foundations (Non-Negotiable)

• Resistance training — the most potent natural testosterone stimulus; compound lifts (squat, deadlift, bench) 3–4×/week
• Sleep optimisation — 7–9 hours; testosterone is primarily released during deep sleep. Sleep apnoea is a major suppressant of testosterone — screen and treat
• Body composition — reducing visceral fat reduces aromatase activity and SHBG; even 10% weight loss can significantly raise testosterone
• Stress management — chronic cortisol elevation suppresses GnRH and LH; HPA axis support is foundational
• Alcohol reduction — alcohol directly suppresses testosterone synthesis and increases aromatase activity

Key Nutraceuticals for Testosterone Support

• Zinc — essential cofactor for testosterone synthesis and 5-alpha reductase; deficiency directly causes low T. 25–45 mg/day with food
• Vitamin D3 — acts as a steroid hormone precursor; VDR receptors are present in Leydig cells. 5,000 IU/day; target serum 25-OH-D of 60–80 ng/mL
• Magnesium — reduces SHBG binding, increasing free testosterone; supports sleep and cortisol regulation. 300–400 mg glycinate or malate
• Ashwagandha (KSM-66) — multiple RCTs show 15–17% increase in testosterone, significant improvements in sperm quality, and reduced cortisol. 600 mg/day
• Tongkat Ali (Eurycoma longifolia) — reduces SHBG, increases free testosterone; adaptogenic; 200–400 mg standardised extract
• Fadogia agrestis — emerging evidence for LH stimulation and testosterone support; use cautiously, long-term safety data limited
• Boron — reduces SHBG and increases free testosterone and DHT; 6–10 mg/day
• DIM — supports healthy oestrogen metabolism; useful when oestradiol is elevated on TRT

DHT, 5-Alpha Reductase & Hair Loss

Testosterone converts to dihydrotestosterone (DHT) via 5-alpha reductase. DHT is more potent than testosterone at androgen receptors and drives prostate growth and male pattern baldness in genetically susceptible men. 5-alpha reductase inhibitors (finasteride, dutasteride) reduce DHT but can cause significant sexual side effects (post-finasteride syndrome) and should be used with caution.

Prostate Health on TRT

The historical concern that TRT causes prostate cancer has been largely refuted by modern evidence. The saturation model suggests that androgen receptors in the prostate are saturated at relatively low testosterone levels — additional testosterone does not proportionally increase prostate cancer risk. However:

• TRT is contraindicated in men with active or suspected prostate cancer
• PSA monitoring is essential — a rise of >1.4 ng/mL in any 12-month period warrants urological evaluation
• Saw palmetto, beta-sitosterol, and lycopene support prostate health as integrative adjuncts

BHRT vs Conventional TRT

The distinction between BHRT and conventional TRT for men is primarily philosophical and sourcing-related:

• Conventional TRT — FDA-approved pharmaceutical testosterone (cypionate, enanthate, gels, patches, oral undecanoate)
• BHRT — typically refers to compounded bioidentical testosterone (pellets, custom-dosed creams, troches); molecularly identical to endogenous testosterone but not FDA-approved as compounded products
• Both use the same testosterone molecule — the difference is in delivery, compounding, and regulatory status
• Compounded BHRT allows more flexible dosing and delivery options but lacks the quality control oversight of FDA-approved products

When TRT May Not Be the Answer

Before initiating TRT, always address reversible causes of low testosterone:

• Obesity and metabolic syndrome — weight loss alone can normalise testosterone
• Sleep apnoea — CPAP treatment significantly raises testosterone
• Nutritional deficiencies (zinc, vitamin D, magnesium)
• Chronic stress and HPA axis dysfunction
• Opioid or medication-induced suppression
• Alcohol excess
• Clomiphene or enclomiphene — for secondary hypogonadism in men who want to preserve fertility or avoid exogenous testosterone